Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.
Arbutus Biopharma Announces Claim Construction Ruling In Ongoing Patent Infringement Lawsuit Against Moderna
The following summarizes the Court's Opinion:Composition of Total Lipid (‘069)The Court agreed with Plaintiffs' position that the claimed molar percentage (mol. %) ranges can be met by any particle and is not limited to
Arbutus Stock Soars 20% After Court Rules Against Moderna In Covid Vaccine Patent Claim
Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court.
Barinthus Bio Said Initial Data From The Combination Of Imdusiran And VTP-300 Show Meaningful Reductions Of HBsAg Levels That Were Maintained Well Below Baseline.
Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline.
In HBV003, 31% of participants with screening HBsAg level of ≤200
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell
• CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell
• Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance
Arbutus Biopharma Corp (NASDAQ:ABUS) reported Q1 2023 revenues of $6.7 million, beating the consensus of $6.02 million. Revenues declined from…
Recap: Arbutus Biopharma Q1 Earnings
Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 4, 2023 at 07:30 AM. Here’s what…